Rieckermann showcases the latest solutions and technologies for pharmaceutical processes at ACHEMA
After a couple of years of travel restrictions, Rieckermann is delighted once again to be attending ACHEMA, the world’s leading trade show for the pharmaceutical process industries, as a team together with international colleagues from Europe, the Middle East, and Asia.
The key topics featured by Rieckermann this year were the latest cutting-edge solutions and technologies for pharmaceutical processes, including tablet pressing, blow-fill-seal, aseptic filing, and solid processing. With the presence of diverse engineering, sales, and technical service specialists, Rieckermann accompanied their customers in finding out about the latest machinery and solutions offered by technology partners such as Glatt, Bausch+Ströbel, Weiler, Körber, and Korsch.
During the exhibition, Rieckermann’s engineering and technical experts provided customized consultancy on local integration in the Middle East and Asia using innovative solutions from the US and Europe. Given the convenience of on-site consultation and information provided by various experts from Rieckermann and their partners, visitors to ACHEMA were able to collect in-depth information all in one place and make swift business decisions on the spot.
Rieckermann has been participating in the ACHEMA exhibition for over 30 years, and this is the fourth time in a row that the company has been represented at the trade show with an exhibition booth of its own. By standing shoulder to shoulder with renowned technology partners at ACHEMA, Rieckermann strengthens their commitment to being a full-service industrial solution provider for the pharmaceutical industry.
ACHEMA 2022 was held from August 22 to 26, 2022 in Frankfurt am Main, Germany. The trade show takes place only once every three years at the Frankfurt Messe, though the next ACHEMA show is scheduled to take place from June 10 to 14, 2024. The most recent show was originally to take place in 2021, but was postponed twice to August 2022 in view of the continuing uncertainty caused by the pandemic.